#USA #Philadelphia #Psychedelic Therapies #MoreBetter #Longevity Research

MoreBetter Launches RWE Co-Investment Program

MoreBetter, Ltd. has recently unveiled its Real World Evidence Co-Investment Program, focusing on therapies such as longevity treatments, peptides, and psychedelics. This innovative initiative aims to provide more in-depth data on patient-reported outcomes through rigorous research efforts.

Background of the Program

The RWE Co-Investment Program allows MoreBetter to integrate its research capabilities into longitudinal studies that track patient experiences and results over time. This program is particularly significant given the rise of these therapies in the medical landscape, despite the lack of comprehensive data regarding their effectiveness and safety.

Program Details

The program is now open to institutions involved in these therapies, including clinics, compounding pharmacies, and brands. Over the first twelve months, MoreBetter plans to co-invest in up to ten studies, carefully designing each one to capture essential patient data, from treatment responses to any adverse effects experienced. The studies utilize MoreBetter's compliant research platform, named Penzai, ensuring a stringent adherence to regulatory standards.

Importance of Data

In various regions across the United States, therapies such as the use of ketamine for psychiatric care and psilocybin for therapeutic purposes are becoming increasingly commonplace. However, many of these treatments remain unregulated, presenting a significant challenge for researchers striving to produce reliable evidence. MoreBetter's RWE program seeks to address this challenge by leveraging patient feedback directly from everyday use of these therapies, collected through simple questionnaires designed for easy participation.

Engaging Patients

Patient engagement is a cornerstone of this initiative. Participants will be prompted through text messages to complete brief surveys that assess their experiences with the therapies being studied. This strategy not only fosters continual participant involvement but also aids in gathering consistent data necessary for longitudinal analysis.

Collaborative Research Efforts

MoreBetter will work alongside twelve university partners to ensure that the studies are robust and grounded in scientific methodology. Each study will use standardized assessment tools, allowing for comparative analysis across various therapies and patient groups.

Regulatory Landscape

The regulatory environment for these therapies is evolving. Recently, the U.S. Department of Health and Human Services (HHS) issued guidelines allowing compounding pharmacies to mix certain peptides under specific conditions. This development reflects a growing recognition of the need for evidence-based research in areas previously deemed too unconventional to explore. Nevertheless, caution remains essential, as many products backed by this co-investment program are still under regulatory scrutiny and not fully approved by the FDA.

Future Prospects

In addition to gathering valuable patient-reported outcomes, MoreBetter is pursuing data partnerships to ensure the linkage of patient experiences with electronic health records, thereby offering an even more in-depth view of therapy outcomes while maintaining patient privacy.

Conclusion

MoreBetter's RWE Co-Investment Program represents a significant step forward in understanding the efficacy of longevity, peptide, and psychedelic therapies through real-world patient inputs. By enabling stakeholders—from providers to regulators—to access comprehensive outcome data, the program aims to enhance the overall understanding of these rapidly developing treatment landscapes. As applications remain open, MoreBetter encourages interested parties in this vital sector to apply and contribute towards shaping the future of health innovation.

More information about the co-investment program can be found at MoreBetter's website or by contacting their office directly.